Unit:
Κατεύθυνση Κλινικές Μελέτες: Σχεδιασμός και ΕκτέλεσηLibrary of the School of Health Sciences
Author:
Aravantinou-Fatorou Aikaterini
Supervisors info:
Ζαγουρή Φλώρα, Αναπληρώτρια Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ
Γκόγκα Ελένη:Παθολόγος Ογκολόγος, Καθηγήτρια- Διευθύντρια, Ιατρική Σχολή ΕΚΠΑ
Γαβριατοπούλου Μαρία: Επίκουρη Καθηγήτρια, Ιατρική Σχολή ΕΚΠΑ
Original Title:
Πεμπρολιζουμάμπη και καρκίνος ενδομητρίου
Translated title:
Pembrolizumab in endometrial cancer
Summary:
Purpose: Immunotherapy and specifically pembrolizumab have shown great results in a variety of cancer types. This is the first systematic review of the literature to synthesize all the available data and to evaluate the efficacy and safety of pembrolizumab in endometrial cancer.
Methods: This study was performed in accordance with the PRISMA guidelines. Eligible articles were identified by a search of MEDLINE and ClinicalTrials.gov databases, using a predefined combination of the terms" endometrial cancer", "humanized monoclonal antibodies"
Results: Overall, 5 articles (99patients) were eligible. Pembrolizumab seems to be an effective and safe therapeutic option for the management of advanced/ metastatic endometrial cancer. Results of ongoing trials either with pembrolizumab alone or in combination with other treatments are expected to update this statement.
Conclusion: Pembrolizumab seems to show clinical activity in endometrial cancer. However, it is unquestionable the need for large Phase III clinical trials in order to verify these results and discover predictive biomarkers.
Main subject category:
Health Sciences
Keywords:
Immuno-oncology, Immunotherapy, Gynecologic cancer, Endometrial cancer
